Business Context and Reporting Period
This Form 8-K Current Report was filed by Establishment Labs Holdings Inc. on December 1, 2022. The filing reports the appointment of a new executive officer effective December 1, 2022.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Paul D. Rodio as Chief Operating Officer (COO), effective December 1, 2022. Mr. Rodio brings prior executive experience from Cardinal Health, Inc., Medtronic, Covidien, and Gates Fluid Power.
Management Commentary and Compensation Details
The Company entered into an Employment Agreement with Mr. Rodio containing the following terms:
- Base Salary: $375,000 annually.
- Annual Bonus: Target amount of 50% of base salary.
- Equity Incentives: Annual equity awards beginning in 2024 with a grant date fair value of approximately 150% of base salary.
- Stock Options: A new hire grant of options to purchase 50,000 common shares. The exercise price is the closing price on the Start Date. Vesting occurs in four equal tranches (25% each) on the first four anniversaries of the Start Date.
Additional terms regarding severance and benefits are consistent with other executive employment agreements referenced in the Company's definitive proxy statement filed on April 29, 2022.
Investor Verification Checklist
- Verify the full text of the Employment Agreement attached as Exhibit 10.1 for specific severance and benefit details.
- Review the definitive proxy statement filed on April 29, 2022, to understand the standard terms for executive compensation and severance referenced in this filing.
- Confirm the vesting schedule and exercise price of the 50,000 stock options granted to Mr. Rodio.